FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on

被引:9
作者
Mullard, Asher
机构
关键词
D O I
10.1038/nrd.2018.206
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A panel of independent experts voted narrowly in favour of continuing to require cardiovascular outcomes data for new diabetes drugs, but urged relaxation and simplification of the safety assessment.
引用
收藏
页码:850 / 851
页数:2
相关论文
empty
未找到相关数据